These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11228793)

  • 21. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
    Eriksson BI; Borris L; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Kälebo P;
    J Thromb Haemost; 2006 Jan; 4(1):121-8. PubMed ID: 16409461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On call. I had a hip replacement operation eight years ago and I've had a wonderful result. Now I'm ready to have my other hip done. Last time, I had blood-thinning shots in the hospital, but this time my orthopedist also wants me to take a pill at home for a month. Is it really necessary?
    Simon HB
    Harv Mens Health Watch; 2005 Nov; 10(4):8. PubMed ID: 16365958
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.
    MacMahon S; Rodgers A; Collins R; Farrell B
    J Bone Joint Surg Br; 1994 Jul; 76(4):521-4. PubMed ID: 8027132
    [No Abstract]   [Full Text] [Related]  

  • 25. Xarelto: a new drug for new joints. Hip and knee recipients can avoid postsurgical clots without undergoing painful injections.
    Johns Hopkins Med Lett Health After 50; 2011 Oct; 23(8):6. PubMed ID: 22059258
    [No Abstract]   [Full Text] [Related]  

  • 26. Prevention of venous thrombosis after elective hip surgery.
    Turpie AG; Kher A
    Orthopedics; 1998 Dec; 21(12):1275-81. PubMed ID: 9867302
    [No Abstract]   [Full Text] [Related]  

  • 27. Antithrombotic therapy after TAVI: where are we going?
    Wilkins B; Fukutomi M; Søndergaard L
    EuroIntervention; 2019 Sep; 15(7):563-565. PubMed ID: 31538625
    [No Abstract]   [Full Text] [Related]  

  • 28. [Critical evaluation of the usefulness of drugs inhibiting platelet function in the prevention of postoperative deep venous thrombosis and in ischemic cardiopathy].
    Verstraete M
    Recenti Prog Med; 1980 Apr; 68(4):361-81. PubMed ID: 6992244
    [No Abstract]   [Full Text] [Related]  

  • 29. Thromboprophylaxis and death after total hip replacement.
    Amstutz HC; Dorey F
    J Bone Joint Surg Br; 1997 Nov; 79(6):1037-8. PubMed ID: 9393928
    [No Abstract]   [Full Text] [Related]  

  • 30. Antiplatelet therapy to prevent thrombosis after hip fracture.
    Warwick DJ
    J Bone Joint Surg Br; 1995 Jan; 77(1):163-4. PubMed ID: 7822384
    [No Abstract]   [Full Text] [Related]  

  • 31. Preoperative stop or continue? New antithrombotic and anticoagulants.
    Ickx BE
    Acta Anaesthesiol Belg; 2001; 52(4):385-93. PubMed ID: 11799571
    [No Abstract]   [Full Text] [Related]  

  • 32. Place of aspirin in prophylaxis of venous thromboembolism.
    Sors H; Meyer G
    Lancet; 2000 Apr; 355(9212):1288-9. PubMed ID: 10776735
    [No Abstract]   [Full Text] [Related]  

  • 33. Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment.
    Pellegrini VD; Sharrock NE; Paiement GD; Morris R; Warwick DJ
    Instr Course Lect; 2008; 57():637-61. PubMed ID: 18399613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Total hip and knee arthroplasty: do obese patients or smokers require a more prolonged thrombosis prophylaxis?].
    Iturbe Hernández T; de Miguel Olmeda R; Cornudella Lacasa R; Gutiérrez Martín M
    Rev Clin Esp; 1999 Aug; 199(8):550-1. PubMed ID: 10522444
    [No Abstract]   [Full Text] [Related]  

  • 35. [Proposal for making guidelines of regional anesthesia in patients under anticoagulation therapy or antiplatelet therapy].
    Hamaguchi S
    Masui; 2014 Oct; 63(10):1069. PubMed ID: 25693330
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes of D-dimer after total hip arthroplasty in patients with and without intraoperative heparin.
    Maezawa K; Nozawa M; Aritomi K; Kubota M; Shitoto K; Kurosawa H
    Arch Orthop Trauma Surg; 2008 Jan; 128(1):37-40. PubMed ID: 17522875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Risk and prevention of venous thromboembolic complications in surgery].
    Baeshko AA
    Khirurgiia (Mosk); 2001; (4):61-9. PubMed ID: 11490498
    [No Abstract]   [Full Text] [Related]  

  • 39. A clinical algorithm to predict the loading dose of phenprocoumon.
    Good AC; Henz S
    Thromb Res; 2007; 120(6):921-5. PubMed ID: 17350082
    [No Abstract]   [Full Text] [Related]  

  • 40. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership.
    Mesko JW; Brand RA; Iorio R; Gradisar I; Heekin R; Leighton R; Thornberry R
    J Arthroplasty; 2001 Sep; 16(6):679-88. PubMed ID: 11547365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.